Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.20.760417

Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study

Ugur, S.·Onal-Suzek, T.
View original source ↗Export metadata ↓

Abstract

Sulforaphane (SFN), a natural isothiocyanate from cruciferous vegetables, exerts neuroprotective effects through mechanisms extending beyond canonical Nrf2/ARE activation. Here, we developed a multi-dataset computational framework integrating transcriptomic analysis, multi-criteria target prioritization, and structural docking evaluation. R- and S-SFN were docked against 693 prioritized targets using AutoDock Vina, followed by cross-validation, brain expression profiling, and molecular dynamics simulations. Four genes (IGSF9, KCNQ5, KCTD12, and NFIX) were dysregulated across all four datasets. Among 693 targets, 88 showed favorable predicted docking scores (deltaG less than or equal to -4.0 kcal/mol), with 65 (73.9%) exhibiting expression in at least one GTEx brain region. Independent cross-validation showed significant enrichment of prioritized targets in an SFN-responsive Alzheimer disease transcriptomic dataset (OR = 1.44, 95% CI: 1.08-1.89, p = 0.0104). Complementary disease gene set enrichment confirmed that 33% of strong hits (29/88) overlap established neurodegeneration gene sets across AD, PD, and ALS - including ACHE, target of FDA-approved anti-AD drugs - with highly significant enrichment across all three disease categories (OR range: 67-127, all p less than 0.001). R-SFN showed a modest but statistically detectable preference over S-SFN across the 88 strong hits (Wilcoxon p = 0.0081; paired t-test p = 0.0047). TMEM45A, GRIK2, and FABP3 emerged as putative neurodegeneration-relevant targets. Molecular dynamics simulations supported the structural stability of R-SFN poses for TMEM45A, GRIK2, and FABP3, while MM-GBSA estimated favorable binding energies for GRIK2 (deltaG_bind = -19.78 kcal/mol) and FABP3 (deltaG_bind = -14.49 kcal/mol). These findings generate testable hypotheses regarding previously underexplored molecular targets that may contribute to the neuroprotective actions of SFN.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ugur, S., Onal-Suzek, T.. 2026-10-25. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study. https://doi.org/10.64898/2026.10.20.760417

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Carrier-Limited Release Risk in Electrospun Nanofibers for Regenerative Endodontics: Constraint Discovery from 25 Formulations

Regenerative endodontics needs an intracanal carrier that keeps disinfecting across a dressing interval that clinicians schedule at one to four weeks, without harming the stem cells that rebuild the pulp. We ask what one completed 25-formulation electrospinning campaign of poly(vinylpyrrolidone) (PVP) fibers carrying metronidazole, ciprofloxacin, minocycline and Ca(OH)2 can decide, and use machine learning for constraint discovery and decision support rather than as a new predictor. After an audit against the source thesis, logistic regression predicts fine-fiber formation at 96% leave-one-out accuracy, but a one-threshold rule does as well, the gain over the 80% majority baseline is not significant (exact McNemar p = 0.125), and accuracy falls to 84% when mixture loading is encoded per component. Diameter models interpolate within formulation families (ridge MAE 193 nm, 95% CI 96 to 317 nm) and fail across them (R^2 < 0). Because the campaign never measured release, we assemble a same-drug, cross-carrier evidence table: 17 bounded metronidazole and ciprofloxacin observations from seven studies, with two-sided censoring. Water-soluble carriers (PVP, PVA) completed release within 80 h (PVP within 8 h); no water-insoluble monolithic carrier reached 90% within its observation window, releasing 1.5 to 50%; both within-study comparisons separate at matched loading; and blend, core-shell and thick-mat architectures released over 3 to 28 days. The PVP mats therefore carry a carrier-limited release risk, not a proven ceiling, and one dissolution experiment can confirm or overturn it. A censoring-aware screen keeps three necessarily and one possibly nondominated formulation, and fixed-budget replays show that uncertainty sampling finds failed formulations sooner, except the one it is confidently wrong about.

bioinformatics↗
bioRxiv2026

CellMethMarker provides an integrated database of human cell- and tissue-type-specific DNA methylation markers

Cell- and tissue-type-specific DNA methylation markers provide epigenetic signatures of cellular identity and are widely used to infer cellular origin from bulk and single-cell methylomes. Existing resources mainly emphasize disease-associated biomarkers, methylome atlases, genomic annotations or RNA-based cell markers, leaving an unmet need for an integrated region-level resource dedicated to such markers. Here we present CellMethMarker (http://gu-zhanglab.hfcas.ac.cn/CellMethMarker), a curated database integrating 347,514 de novo markers derived from uniformly processed whole-genome and reduced-representation bisulfite sequencing datasets, 2,203,507 literature-derived marker records and harmonized metadata for 2,810 samples. CellMethMarker enables cell- and tissue-centered marker retrieval, coordinate-based search, genome-browser visualization, interactive methylation analysis and data download. In an independent single-cell methylome atlas, these markers recover the expected cell-type-associated methylation patterns, and a platform-matched reference built from them lowers the mean deconvolution error from 0.365 to 0.144. CellMethMarker therefore links region-level DNA methylation variation to cellular identity and supports methylome-based cell-type annotation and deconvolution.

bioinformatics↗
bioRxiv2026

IG-28 enables identification and quantification of high-confidence isoforms from large bulk and single-cell full-length cDNA datasets

The technology to sequence full-length transcriptomes from bulk and single-cell samples has rapidly advanced. As a result, full-length cDNA datasets now reach billions of reads in size which is beyond the capability of most established isoform identification tools. Here, we introduce IG-28 which addresses this challenge with its capability to process and analyze large fl-cDNA datasets fast and using minimal computational resources. In contrast to its predecessor Mandalorion, IG-28 is not limited to bulk fl-cDNA but is capable of parsing, processing, and analyzing single-cell fl-cDNA datasets. It does so in a lightweight, flexible manner, integrating seamlessly with established scRNA-seq analysis workflows. We benchmarked IG-28 against a variety of established and new isoform identification tools using several bulk and a complex single-cell fl-cDNA dataset and found that IG-28 consistently outperformed the other tools by identifying high-confidence public isoforms.

bioinformatics↗